At its 2026 Annual Meeting of Shareholders held on June 11, 2026, Insight Molecular Diagnostics Inc. shareholders approved an amendment to the company's 2018 Equity Incentive Plan. The amendment increases the total number of common shares authorized for issuance under the plan by 1,750,000, bringing the new total to 5,550,000 shares. Additionally, shareholders elected four directors—Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman—to serve until the 2027 annual meeting. The meeting also resulted in the ratification of CBIZ CPAs P.C. as the independent accounting firm and the non-binding approval of executive compensation. Insight Molecular Diagnostics Inc. operates in the molecular diagnostics industry.